Xencor, Inc. (XNCR) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-25

How it makes money

It earns revenue from milestone payments and royalties paid by larger pharmaceutical partners that commercialize drugs developed using its proprietary XmAb protein engineering technologies.

It operates as a clinical-stage biopharmaceutical company that designs engineered antibody therapeutics and specialized Fc domain technologies. Rather than relying on direct product sales from its own commercial infrastructure, it generates revenue primarily through licensing agreements, development milestones, and royalty payments from partners such as Alexion and Incyte who advance and market medicines incorporating its XmAb technologies.

Financial results depend heavily on the timing and success of partner-led clinical development and regulatory approvals. For example, royalty revenue under the Alexion Agreement reached $70.1 million in 2025, up from $58.2 million in 2024, driven by sales of Ultomiris. Meanwhile, milestone revenue fluctuates based on partner achievements, such as Incyte's regulatory filings and study initiations that triggered milestone payments totaling tens of millions of dollars during 2025.

What protects it: the moat

It protects its earnings by holding patents covering its modular XmAb protein engineering technologies, though it faces ongoing risks that competitors or partners might challenge or infringe these rights.

Competitive advantage rests on proprietary protein engineering platforms such as its XmAb bispecific Fc domains, immune inhibitor Fc domains, and Xtend half-life extension technologies. Management asserts that these modular designs provide differentiated binding properties and therapeutic functions that are difficult for competitors to replicate.

However, management acknowledges significant vulnerabilities regarding intellectual property protection. The company relies heavily on maintaining enforceable patent rights and preventing trade secret disclosure. If it fails to secure and maintain adequate patent protection, or if third parties successfully challenge its intellectual property or claim patent infringement, competitors may be able to commercialize substantially similar products.

What could damage it

Its earnings could be permanently impaired if key commercial partners terminate their agreements or fail to successfully develop and market medicines utilizing its XmAb technologies.

Because a substantial portion of its revenue depends on royalties and milestone payments generated by larger pharmaceutical partners like Alexion and Incyte, any disruption to these collaborations directly attacks its primary source of income. If a partner encounters clinical delays, regulatory rejections, manufacturing failures, or decides to abandon a partnered program such as Ultomiris or tafasitamab, the anticipated milestone payments and ongoing royalty streams would be severely reduced or eliminated.

About Xencor, Inc.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Other companies in Biotechnology